Castration resistant metastatic disease is the major cause of morbidity and mortality in men with advanced prostate cancer. The molecular mechanisms underlying metastasis and castration resistance are both varied and only partially defined. Novel targets and therapies directed against these targets are urgently needed to combat advanced prostate cancer. Likewise, rational combination therapies directed against multiple critical targets are urgently needed. We have recently identified and

Public Health Relevance

Prostate cancer is the second leading cause of cancer-related death in the U.S. Patients with metastatic castrate resistant disease need improved treatments, particularly those who fail the newest anti-androgens. This proposal explores the role of N-cadherin as a potential novel target for advanced prostate cancer and develops a candidate antibody therapeutic that can be advanced to the clinic to manage these patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA092131-11A1
Application #
8555082
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2001-07-01
Project End
2018-08-31
Budget Start
2013-09-18
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$256,992
Indirect Cost
$79,767
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Zumsteg, Zachary S; Chen, Zinan; Howard, Lauren E et al. (2017) Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate 77:1592-1600
Freedland, Stephen J; Vidal, Adriana C; Howard, Lauren E et al. (2017) Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer 123:4199-4206
Tan, Nelly; Lin, Wei-Chan; Khoshnoodi, Pooria et al. (2017) In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer. Radiology 283:130-139
Klaassen, Zachary; Howard, Lauren E; de Hoedt, Amanda et al. (2017) Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer 123:1528-1535
Minciacchi, Valentina R; Spinelli, Cristiana; Reis-Sobreiro, Mariana et al. (2017) MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. Cancer Res 77:2306-2317
Flores, Aimee; Schell, John; Krall, Abigail S et al. (2017) Lactate dehydrogenase activity drives hair follicle stem cell activation. Nat Cell Biol 19:1017-1026
Wang, Piwen; Solorzano, Walter; Diaz, Tanya et al. (2017) Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp 13:1-11
Priester, Alan; Natarajan, Shyam; Khoshnoodi, Pooria et al. (2017) Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. J Urol 197:320-326
Shenoy, T R; Boysen, G; Wang, M Y et al. (2017) CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann Oncol 28:1495-1507
Collins, Jeffrey; Waldmann, Christopher M; Drake, Christopher et al. (2017) Production of diverse PET probes with limited resources: 24 18F-labeled compounds prepared with a single radiosynthesizer. Proc Natl Acad Sci U S A 114:11309-11314

Showing the most recent 10 out of 315 publications